In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: A study of the Southeast Netherlands breast cancer consortium

Annals of Oncology

Volumn 27, Issue 2, 2016, Pages 256-262

  Lobbezoo, D J A ^a,b   Van Kampen, R J W ^a   Voogd, A C ^a,c   Dercksen, M W ^b   Van Den Berkmortel, F ^d   Smilde, T J ^e   Van De Wouw, A J ^f   Peters, F P J ^g   Van Riel, J M G H ^h   Peters, N A J B ⁱ   De Boer, M ^a   Peer, P G M ^j   Tjan Heijnen, Vivianne C G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c Netherlands Comprehensive Cancer Organisation   (Netherlands)

^d Atrium Orbis Medical Center Heerlen Sittard   (Netherlands)

^e JEROEN BOSCH HOSPITAL   (Netherlands)

^f VIECURI MEDICAL CENTER   (Netherlands)

^g Orbis Medical Centre Sittard   (Netherlands)

^h Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

ⁱ St Jans Hospital   (Netherlands)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Chemotherapy; Endocrine therapy; Hormone receptor; Metastatic breast cancer; Outcome

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AGE; AGED; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; COMORBIDITY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 84961654629     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv544     Document Type: Article

References (25)

1. Dawood S, Broglio K, Gonzalez-Angulo AM et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2008; 26: 4891-4898.
2. Chia SK, Speers CH, D'yachkova Y et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110: 973-979.
3. Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20: 1771-1785.
4. Cardoso F, Costa A, Norton L et al. ESO-ESMO 2nd International Consensus guidelines for advanced breast cancer (ABC2). Breast 2014; 23: 489-502.
5. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003; 21: 28-34.
6. Gradishar WJ, Anderson BO, Blair SL et al. National Comprehensive Cancer Network Breast Cancer Pane. Breast cancer version 3.2014. J Natl Compr Cancer Netw 2014; 12: 542-590.
7. Partridge AH, Rumble RB, Carey LA et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32: 3307-3329.
8. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormonereceptor- positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
9. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual. New York:Springer 2002.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
11. Gao S, Barber B, Schabert V, Ferrufino C. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe. Curr Med Res Opin 2012; 28: 1111-1118.
12. Donato BM, Burns L, Willey V et al. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine:a descriptive report. Clin Ther 2010; 32: 546-554.
13. van Herk-Sukel MP, van de Poll-Franse LV, Creemers GJ et al. Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands. Breast J 2013; 19: 394-401.
14. Seah DS, Luis IV, Macrae E et al. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw 2014; 12: 71-80.
15. Swallow E, Zhang J, Thomason D et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. Curr Med Res Opin 2014; 30: 1537-1545.
16. Andre F, Neven P, Marinsek N et al. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Curr Med Res Opin 2014; 30: 1007-1016.
17. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 2014; 110: 551-555.
18. Beslija S, Bonneterre J, Burstein H et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007; 18: 215-225.
19. Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003; 1(2): CD002747.
20. Cheng SH, Wang CJ, Lin JL et al. Adherence to quality indicators and survival in patients with breast cancer. Med Care 2009; 47: 217-225.
21. Hebert-Croteau N, Brisson J, Latreille J et al. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 2004; 22: 3685-3693.
22. International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2002; 94: 1054-1065.
23. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 1658-1667.
24. Cardoso F, Bischoff J, Brain E et al. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 2013; 39: 457-465.
25. Johnston SR, Schiavon G. Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy-overcoming resistance and introducing new agents. Am Soc Clin Oncol Educ Book 2013; doi:10.1200/EdBook_AM.2013.33.e28.